Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Multicenter Analysis of Patients with Bullous Pemphigoid: Clinical Characteristics and Insights into Drug-Associated Disease.

International journal of molecular sciences·2026

Same author

Effect of Inulin-Type Fructans on Body Composition, Carbohydrate Metabolism and Energy Expenditure in Patients with Psoriasis: Results of INGUTSKIN Randomized Controlled Trial.

Nutrients·2026

Same author

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa-A Narrative Review.

Dermatology and therapy·2026

Same author

Factors Affecting Wound Healing in Patients with Venous Leg Ulcers: A Pilot Study.

Nutrients·2026

Same author

Extragenital Lichen Sclerosus: A Review of the Literature.

Dermatology and therapy·2026

Same author

INulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.

Nutrition journal·2026

Search research articles

Related Experiment Video

Updated: Aug 26, 2025

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

Cyclosporine-induced gingival overgrowth-Review.

Joanna Chojnacka-Purpurowicz¹, Ewa Wygonowska¹, Waldemar Placek¹

¹Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of Warmia and Mazury, Olsztyn, Poland.

Dermatologic Therapy

|October 8, 2022

Summary

Drug-induced gingival overgrowth (DIGO) is a side effect of certain medications. Cyclosporine A (CsA) can cause this condition, particularly in young males, leading to serious oral health issues.

Keywords:

DIGO calcineurin inhibitor cyclosporine gingival overgrowth gingivectomy

More Related Videos

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

Published on: January 12, 2019

Isolation, Characterization and Functional Examination of the Gingival Immune Cell Network

Isolation, Characterization and Functional Examination of the Gingival Immune Cell Network

Published on: February 16, 2016

Related Experiment Videos

Last Updated: Aug 26, 2025

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

Published on: January 12, 2019

Isolation, Characterization and Functional Examination of the Gingival Immune Cell Network

Isolation, Characterization and Functional Examination of the Gingival Immune Cell Network

Published on: February 16, 2016

Area of Science:

Oral Medicine
Pharmacology
Periodontology

Background:

Drug-induced gingival overgrowth (DIGO) is an adverse effect of phenytoin, calcium channel blockers, and cyclosporine A (CsA).
This condition involves fibrous gingival enlargement, potentially leading to gingivitis, periodontitis, and tooth loss.
Consequences include worsening dental caries, pain, difficulty eating, bleeding gums, and halitosis.

Purpose of the Study:

To review the literature on cyclosporine A-induced gingival hyperplasia (CiGHO).
To discuss the knowns and unknowns of CiGHO's pathomechanism and clinical presentation.

Main Methods:

This paper is a review of existing literature on drug-induced gingival overgrowth, with a focus on CsA.

Main Results:

CiGHO is more prevalent in male children and adolescents.
Poor oral hygiene correlates with increased severity of gingival overgrowth.
Tartar and local irritant removal can alleviate symptoms.

Conclusions:

Conventional gingivectomy is a treatment option for DIGO.
Further research is needed to elucidate the pathomechanism of CsA-induced gingival hyperplasia.